RU2582916C2 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция Download PDF

Info

Publication number
RU2582916C2
RU2582916C2 RU2011144307/15A RU2011144307A RU2582916C2 RU 2582916 C2 RU2582916 C2 RU 2582916C2 RU 2011144307/15 A RU2011144307/15 A RU 2011144307/15A RU 2011144307 A RU2011144307 A RU 2011144307A RU 2582916 C2 RU2582916 C2 RU 2582916C2
Authority
RU
Russia
Prior art keywords
peptide
seq
antigenic
aci
mice
Prior art date
Application number
RU2011144307/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011144307A (ru
Inventor
ПФАЙФЕР Андреа
МУС Андреас
ВАН-ЛЁВЕН Фред
ПИЛГРЕН Мария
Original Assignee
Ац Иммуне С.А.
Католике Универзитайт Лёвен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2582916(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ац Иммуне С.А., Католике Универзитайт Лёвен filed Critical Ац Иммуне С.А.
Publication of RU2011144307A publication Critical patent/RU2011144307A/ru
Application granted granted Critical
Publication of RU2582916C2 publication Critical patent/RU2582916C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
RU2011144307/15A 2009-04-03 2010-04-01 Фармацевтическая композиция RU2582916C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157303.0 2009-04-03
EP09157303 2009-04-03
PCT/EP2010/054418 WO2010115843A2 (en) 2009-04-03 2010-04-01 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
RU2011144307A RU2011144307A (ru) 2013-05-10
RU2582916C2 true RU2582916C2 (ru) 2016-04-27

Family

ID=42269736

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011144307/15A RU2582916C2 (ru) 2009-04-03 2010-04-01 Фармацевтическая композиция

Country Status (28)

Country Link
US (3) US8647631B2 (cg-RX-API-DMAC7.html)
EP (2) EP3097925B1 (cg-RX-API-DMAC7.html)
JP (2) JP5810076B2 (cg-RX-API-DMAC7.html)
KR (2) KR20150041203A (cg-RX-API-DMAC7.html)
CN (2) CN105524160B (cg-RX-API-DMAC7.html)
AU (1) AU2010233856B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015088B1 (cg-RX-API-DMAC7.html)
CA (1) CA2757345C (cg-RX-API-DMAC7.html)
CL (2) CL2011002457A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390113A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110509A (cg-RX-API-DMAC7.html)
DK (2) DK3097925T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011367A (cg-RX-API-DMAC7.html)
ES (2) ES2595371T3 (cg-RX-API-DMAC7.html)
HU (2) HUE044981T2 (cg-RX-API-DMAC7.html)
IL (1) IL215451A (cg-RX-API-DMAC7.html)
MA (1) MA34120B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011010353A (cg-RX-API-DMAC7.html)
MY (1) MY171300A (cg-RX-API-DMAC7.html)
NZ (1) NZ595856A (cg-RX-API-DMAC7.html)
PL (2) PL2413957T3 (cg-RX-API-DMAC7.html)
PT (2) PT2413957T (cg-RX-API-DMAC7.html)
RU (1) RU2582916C2 (cg-RX-API-DMAC7.html)
SG (1) SG175037A1 (cg-RX-API-DMAC7.html)
SI (2) SI3097925T1 (cg-RX-API-DMAC7.html)
UA (1) UA107571C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010115843A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107776B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
RU2789459C2 (ru) * 2016-12-01 2023-02-03 Сангамо Терапьютикс, Инк. Модуляторы тау и способы и композиции для их доставки
US12318427B2 (en) 2018-10-02 2025-06-03 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
DK2408807T3 (da) * 2009-03-18 2021-08-09 Ac Immune Sa Fremgangsmåde til terapeutisk anvendelse
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5917394B2 (ja) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
KR20210099167A (ko) 2011-09-19 2021-08-11 악손 뉴로사이언스 에스이 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단
EP3135689B1 (en) * 2011-10-07 2018-12-19 AC Immune S.A. Phosphospecific antibodies recognising tau
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
RU2657438C2 (ru) * 2012-05-31 2018-06-13 Осака Сити Юниверсити Терапевтическое средство или профилактическое средство против деменции
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
AU2013302540B2 (en) * 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
KR102233349B1 (ko) * 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
SG11201605044RA (en) 2013-12-20 2016-07-28 Hoffmann La Roche HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
CA3258972A1 (en) 2015-06-05 2025-04-17 Ac Immune Sa TAU ANTIBODIES AND METHODS OF USING THEM
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
WO2018106781A1 (en) 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
EP3700556A2 (en) 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
BR112021014794A2 (pt) * 2019-02-08 2021-10-05 Ac Immune S.A. Método de administração segura de vacina de peptídeo de tau fosforilada
US11591377B2 (en) 2019-04-24 2023-02-28 Janssen Pharmaceuticals, Inc. Heterologous administration of tau vaccines
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
CA3243636A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg CONJUGATED COMPRISING AT LEAST ONE β-GLUCANE OR ONE MANNANA
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003739B1 (ru) * 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
WO2002004949A2 (en) 2000-07-11 2002-01-17 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
EP1581203A1 (en) 2002-12-24 2005-10-05 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
ES2407429T3 (es) * 2005-12-12 2013-06-12 Ac Immune S.A. Vacuna terapéurica
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
JPWO2009051220A1 (ja) 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
DK2408807T3 (da) * 2009-03-18 2021-08-09 Ac Immune Sa Fremgangsmåde til terapeutisk anvendelse
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5917394B2 (ja) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
AU2010277254B2 (en) 2009-07-30 2015-05-07 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003739B1 (ru) * 1997-12-03 2003-08-28 Байоджен, Инк. Гидрофобно-модифицированные белки, способы их получения и их применение

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAROLINE SMET " Etude des interactions entre la peptidyl-prolyl cis/trans isomerase Pin1 et la proteine microtubulaire tau/ Recherche d"inhibiteurs ciblant la liaison de Pin1 a ses substrats phosphoreles. THESE pour l"obtention du grade de Docteur de l"universite de Lille 2, 18 Оctobre 2004, CAROLINE SMET " The peptidyl-prolyl cis/trans isomerase Pin1 Recognizes the phospho-Thr212-Pro213 site on tau", Biochemistry, 2004, 43, 2032-2040. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
RU2789459C2 (ru) * 2016-12-01 2023-02-03 Сангамо Терапьютикс, Инк. Модуляторы тау и способы и композиции для их доставки
US12318427B2 (en) 2018-10-02 2025-06-03 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
RU2833931C2 (ru) * 2019-05-02 2025-01-31 Дойчес Центрум Фюр Нойродегенеративе Эркранкунген Е.В. (Дцне) Иммуноген для предотвращения или лечения семейной лобно-височной деменции (лвд) и/или бокового амиотрофического склероза (бас)

Also Published As

Publication number Publication date
HUE030428T2 (en) 2017-05-29
HK1164127A1 (en) 2012-09-21
UA107571C2 (xx) 2015-01-26
SI3097925T1 (sl) 2019-11-29
CL2011002457A1 (es) 2012-03-16
ZA201107776B (en) 2014-03-26
CR20110509A (es) 2012-02-09
IL215451A0 (en) 2011-12-29
MA34120B1 (fr) 2013-04-03
ECSP11011367A (es) 2012-03-30
AU2010233856A1 (en) 2011-10-27
EP3097925A1 (en) 2016-11-30
CN105524160A (zh) 2016-04-27
CA2757345C (en) 2020-04-14
ES2595371T3 (es) 2016-12-29
CA2757345A1 (en) 2010-10-14
BRPI1015088B1 (pt) 2021-06-29
KR20150041203A (ko) 2015-04-15
CN102946899B (zh) 2016-01-20
BRPI1015088A2 (pt) 2016-06-28
JP5810076B2 (ja) 2015-11-11
MX2011010353A (es) 2011-12-06
PT2413957T (pt) 2016-09-30
DK3097925T3 (da) 2019-08-05
MY171300A (en) 2019-10-07
IL215451A (en) 2016-05-31
HUE044981T2 (hu) 2019-12-30
EP2413957B1 (en) 2016-07-27
CO6390113A2 (es) 2012-02-29
NZ595856A (en) 2014-05-30
RU2011144307A (ru) 2013-05-10
EP2413957A2 (en) 2012-02-08
SG175037A1 (en) 2011-11-28
PL3097925T3 (pl) 2020-02-28
DK2413957T3 (en) 2016-10-10
HK1231408A1 (en) 2017-12-22
JP2012522754A (ja) 2012-09-27
CL2013002888A1 (es) 2014-09-05
WO2010115843A3 (en) 2010-12-02
JP2015214559A (ja) 2015-12-03
EP3097925B1 (en) 2019-06-12
PT3097925T (pt) 2019-07-23
AU2010233856B2 (en) 2014-04-10
US20120183599A1 (en) 2012-07-19
US8647631B2 (en) 2014-02-11
CN102946899A (zh) 2013-02-27
ES2738623T3 (es) 2020-01-24
AU2010233856A2 (en) 2011-10-27
PL2413957T3 (pl) 2017-01-31
WO2010115843A2 (en) 2010-10-14
US20140255412A1 (en) 2014-09-11
SI2413957T1 (sl) 2016-12-30
KR101770436B1 (ko) 2017-08-23
KR20120034609A (ko) 2012-04-12
US20150259406A1 (en) 2015-09-17
CN105524160B (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
RU2582916C2 (ru) Фармацевтическая композиция
CN102428101B (zh) 用于治疗用途的方法
CN101330923B (zh) 治疗性疫苗
US9289488B2 (en) Vaccine engineering
HK1231408B (en) Pharmaceutical composition
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
HK1164127B (en) Pharmaceutical composition
HK1127486B (zh) 治疗性疫苗